Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PR domain zinc finger protein 8 (PRDM8) is a transcription factor of the PRDM protein family, characterized by a PR (PRDI-BF1 and RIZ1 homology) domain and multiple C2H2-type zinc finger motifs[2][3]. It is involved in the epigenetic regulation of gene expression by modulating chromatin structure, either through direct or indirect histone methylation[2]. PRDM8 plays a critical role in neuronal cell differentiation and survival in the retina and broader central nervous system, acting as an essential regulator of cell fate during development[1]. Mutations in PRDM8 are linked to neurological disorders, including developmental epileptic encephalopathies. The protein’s dual regulatory role—as either a transcriptional activator or repressor—is context-dependent, and dysregulation has been implicated in cancer and neurodevelopmental disorders[1][2]. PRDM8 is an emerging but not yet widely exploited therapeutic target, with the broader PRDM family subject to ongoing oncology drug discovery efforts.
Not applicable; no known therapeutic drugs directly target PRDM8, but inhibition of PR domain or zinc finger function is a theoretical approach[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PR domain zinc finger protein 8 (PRDM8).